• LAST PRICE
    1.7500
  • TODAY'S CHANGE (%)
    Trending Down-0.0200 (-1.1299%)
  • Bid / Lots
    1.7400/ 119
  • Ask / Lots
    1.8400/ 8
  • Open / Previous Close
    1.7500 / 1.7700
  • Day Range
    Low 1.7400
    High 1.7700
  • 52 Week Range
    Low 1.1600
    High 3.4092
  • Volume
    271,983
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.75
TimeVolumeIMAB
09:32 ET117831.76
09:34 ET6001.75
09:36 ET173921.75
09:38 ET17301.75
09:39 ET26801.75
09:41 ET4021.75
09:43 ET4001.75
09:48 ET2001.755
09:54 ET3001.755
09:56 ET1001.76
09:57 ET3001.755
10:01 ET113511.745
10:03 ET102111.75
10:06 ET21231.75
10:08 ET9701.75
10:10 ET6961.75
10:12 ET5671.75
10:14 ET13801.75
10:15 ET17061.75
10:21 ET3841.75
10:24 ET20061.755
10:26 ET11241.758
10:30 ET1001.755
10:33 ET3211.76
10:44 ET4501.7599
10:46 ET3921.755
11:04 ET10031.7594
11:08 ET1141.755
11:09 ET2201.755
11:11 ET3001.755
11:13 ET1691.7599
11:22 ET2251.755
11:24 ET5561.75
11:26 ET20001.75
11:27 ET1001.75
11:29 ET2901.75
11:40 ET1001.75
11:42 ET5531.7595
11:44 ET11061.75
11:45 ET8951.75
11:49 ET57041.755
11:54 ET2821.75
11:56 ET3071.75
11:58 ET9961.75
12:00 ET48571.75
12:02 ET1001.755
12:03 ET18921.75
12:05 ET6891.75
12:07 ET10661.75
12:09 ET2001.75
12:14 ET1001.75
12:16 ET6751.75
12:18 ET144521.75
12:20 ET5001.75
12:21 ET9791.75
12:23 ET10701.76
12:25 ET9861.75
12:27 ET9661.75
12:30 ET17631.7581
12:32 ET18891.75
12:34 ET6871.75
12:36 ET3971.75
12:38 ET11481.75
12:39 ET9561.75
12:41 ET15641.75
12:43 ET11101.75
12:50 ET4461.75
12:52 ET2001.75
12:54 ET2001.755
12:59 ET1001.75
01:01 ET4821.75
01:06 ET1001.755
01:10 ET2001.75
01:12 ET4381.75
01:14 ET3001.75
01:24 ET1001.75
01:26 ET155401.75
01:28 ET1001.75
01:30 ET3001.75
01:32 ET3031.75
01:33 ET11761.75
01:35 ET8991.7507
01:37 ET4031.755
01:39 ET3811.75
01:42 ET16681.75
01:46 ET4401.75
01:48 ET79191.75
01:50 ET82441.75
01:51 ET2861.75
01:55 ET5771.75
01:57 ET5081.75
02:00 ET2911.75
02:02 ET12761.75
02:04 ET31541.75
02:06 ET8921.7408
02:08 ET7061.75
02:09 ET4081.75
02:11 ET13481.75
02:13 ET7681.745
02:15 ET7591.75
02:18 ET70901.7489
02:20 ET8961.75
02:22 ET101471.75
02:24 ET7901.75
02:26 ET2891.745
02:27 ET5611.75
02:29 ET58671.745
02:31 ET6871.745
02:33 ET58241.75
02:36 ET17481.745
02:38 ET6991.745
02:40 ET13491.75
02:42 ET5961.745
02:44 ET7411.75
02:45 ET1001.75
02:47 ET1001.75
02:49 ET2001.75
02:56 ET2001.75
03:00 ET2001.75
03:02 ET10091.75
03:03 ET3701.75
03:05 ET6841.75
03:07 ET1001.75
03:12 ET1001.75
03:14 ET2001.75
03:18 ET1001.75
03:20 ET1001.75
03:21 ET1001.75
03:25 ET4921.75
03:27 ET66691.75
03:30 ET21691.745
03:32 ET41841.745
03:34 ET74001.75
03:36 ET22081.75
03:38 ET4981.745
03:41 ET29781.745
03:43 ET12831.745
03:45 ET21651.75
03:48 ET18061.75
03:50 ET4941.75
03:52 ET13001.748
03:54 ET9771.75
03:56 ET4481.75
03:59 ET12261.75
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIMAB
I-Mab
141.5M
-0.7x
---
United StatesPYPD
PolyPid Ltd
20.7M
-0.3x
---
United StatesPMCB
PharmaCyte Biotech Inc
17.8M
-1.3x
---
United StatesKALA
KALA BIO Inc
18.4M
-0.4x
---
United StatesIBIO
Ibio Inc
17.1M
-0.2x
---
United StatesAPM
Aptorum Group Ltd
26.0M
-5.2x
---
As of 2024-05-18

Company Information

I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.

Contact Information

Headquarters
Suite 400, 2440 Research BlvdROCKVILLE, MD, United States 20850
Phone
301-670-2800
Fax
---

Executives

Interim Independent Chairman of the Board
Pamela Klein
Chief Executive Officer, Director
Rajkumar Kannan
Chief Financial Officer
Joseph Skelton
Executive Vice President, Chief Business Officer
Weimin Tang
Chief Communications Officer
Gigi Qi Feng

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$141.5M
Revenue (TTM)
$3.8M
Shares Outstanding
80.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.09
EPS
$-2.44
Book Value
$2.95
P/E Ratio
-0.7x
Price/Sales (TTM)
37.0
Price/Cash Flow (TTM)
---
Operating Margin
-5,059.30%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.